Prestige Consumer Healthcare vs USANA Health Sciences
PBH and USNA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PBH and USNA compare
Prestige Consumer Healthcare is the larger company, worth 8.9 times as much as USANA Health Sciences ($2.2B against $245M).
Prestige Consumer Healthcare grew revenue faster over the last twelve months (5.1% versus −0.78% for USANA Health Sciences).
Prestige Consumer Healthcare keeps more of each dollar of sales as profit, with a net margin of 13.3% compared with −2.3% at USANA Health Sciences.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PBH | USNA |
|---|---|---|
| Size and price | ||
| Market cap | $2.2B | $245M |
| Share price | $46.19 | $13.24 |
| Change, 1 year | −23.7% | −31.7% |
| Change, 5 years | −20.7% | −87.0% |
| Beta (5Y) | 0.44 | 0.65 |
| Employees | 890 | 1,570 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 5 (better) | 4 |
| Growth score | 1 (better) | 0 |
| Performance score | 3 (better) | 2 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.3× | – |
| P/S | 1.9× | 0.3× (better) |
| P/B | 1.1× | 0.5× (better) |
| EV/EBITDA | 12.9× | 2.3× (better) |
| P/FCF | 10.2× | 8.3× (better) |
| FCF yield | 9.8% | 12.1% (better) |
| Fair value | $65.23 | $31.52 |
| Margin of safety | 29.2% | 58.0% (better) |
| Growth | ||
| Revenue growth (TTM) | 5.1% (better) | −0.78% |
| Revenue growth, 5Y average | 2.9% (better) | −4.0% |
| Net income growth (TTM) | −22.8% (better) | −225% |
| EPS growth (TTM) | −19.6% (better) | −231% |
| EPS growth, 5Y average | 3.8% (better) | −37.0% |
| Profitability | ||
| Gross margin | 52.5% | 77.3% (better) |
| Operating margin | 25.0% (better) | −0.41% |
| Net margin | 13.3% (better) | −2.3% |
| FCF margin | 18.4% (better) | 3.3% |
| Return on equity | 8.2% (better) | −4.0% |
| Return on invested capital | 8.1% (better) | −0.81% |
| Financial health | ||
| Debt / equity | 1.07 (better) | 0.00 |
| Net debt / EBITDA | 6.20 | – |
| Interest coverage | – | −9.4× |
| Current ratio | 2.92 (better) | 2.59 |
| Altman Z-score | 1.54 | 3.50 (better) |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | 2.1% (better) | 0.00% |
| Shareholder yield | 2.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 113% | 66.2% |
| Held by insiders | 1.4% | 40.9% |
| Insider net buying, 12 months | −$203K (better) | −$895K |
| Short interest, % of float | 9.1% | 8.1% |
Go deeper
- PBH stock overview
- PBH income statement
- PBH valuation and score
- USNA stock overview
- USNA income statement
- USNA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.